ZBH
NYSEZIMMER BIOMET HOLDINGS, INC.
Technology · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$6.8B
2021
$6.9B
2022
$7.4B
2023
$7.7B
2024
$8.2B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$8.2B
Net Income$705.1M
Gross Profit—
Oper Income$1.1B
EPS (dil)$3.55
Rev/sh$42.55
FCF/sh$7.61
Book/sh$65.68
Gross M—
Oper M13.3%
Profit M8.6%
FCF M17.9%
ROE5.5%
ROA3.1%
ROIC4.7%
R&D/Rev2.7%
Rev Y/Y7.2%
Rev 3Y CAGR5.9%
EPS Y/Y-19.9%
EPS 3Y CAGR47.8%
FCF 3Y CAGR8.0%
Payout27%
Div/sh$0.96
Shs Chg Y/Y-2.6%
Current Ratio1.98
Quick Ratio1.10
Debt/Eq0.59
Int Coverage—
Net Debt$6.9B
Total Debt$7.5B
Cash & Eq$591.9M
Total Assets$23.1B
Oper CF$1.7B
Capex$224.5M
Free CF$1.5B
Buybacks$487.0M
Equity$12.7B
Liabilities$10.4B
Shs Outstand0.19B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $6.8B | $6.9B | $7.4B | $7.7B | $8.2B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $860.3M | $696.3M | $1.3B | $1.3B | $1.1B |
| Net Income | $402.1M | $232.4M | $1.0B | $905.3M | $705.1M |
| Diluted EPS | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 |
| Operating Cash Flow | $1.4B | $1.4B | $1.6B | $1.5B | $1.7B |
| Free Cash Flow | $1.3B | $1.2B | $1.3B | $1.3B | $1.5B |
COMMUNITY · $ZBH0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.